Reilly Osadchey

Reilly Osadchey

Auto-generated profile, based on publicly available information

Reilly Osadchey

Department of Chemistry

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
ROReilly Osadchey
Reilly Osadchey
KNKwangho Nam
Kwangho Nam
QCQiang Cui
Qiang Cui

9 April 2026 in ACS Central Science
Verified
Journal Article
Open access
MMManuel L. Merz
Manuel L. Merz
VSVeronika M. Shoba
Veronika M. Shoba
RPRajaiah Pergu
Rajaiah Pergu
ZSZachary C. Severance
Zachary C. Severance
DGDhanushka N. P. Munkanatta Godage
Dhanushka N. P. Munkanatta Godage
ACAmit Choudhary
Amit Choudhary
The active site’s electric field is integral to enzymatic catalysis (e.g., substrate recognition), and nature employs charge-altering post-translational modifications (e.g., phosphorylation) to perturb this electric field and regulate enzymes. A chromosomal translocation converts Abelson kinase (ABL) to BCR-ABL, the hyperactivity of which drives several cancers. Here, we developed a small molecule, BRD8833, that induces BCR-ABL phosphorylation, which perturbs its active site’s electric field with loss of hyperactivity. Unlike “occupancy-driven” inhibitors that require stoichiometric concentrations, BRD8833 operates through an event-driven, substoichiometric mechanism by inducing the proximity between two BCR-ABL molecules to trigger the inhibitory phosphorylation and selective apoptosis of BCR-ABL-dependent cancer cells. Furthermore, BRD8833 is effective against other oncogenic ABL fusions or clinically observed resistance mutations, including those to occupancy-driven drugs with the same binding site as BRD8833, suggesting differences in their resistance mechanisms. These studies lay the foundation for electric-field and “event-driven” modalities to control hyperactive enzymes with orthogonal resistance mechanisms to occupancy-driven drugs.

14 January 2026 in ChemRxiv
Verified
Preprint
Open access
PDF file
MVMatthew Vince
Matthew Vince
ROReilly Osadchey
Reilly Osadchey
JLJocelyn Lotterhos
Jocelyn Lotterhos
CDChristopher DeNyse
Christopher DeNyse
DDDaniel Dietrich
Daniel Dietrich
AWAdrian Whitty
Adrian Whitty
Several influential studies published around the turn of the millennium reported that advancing a lead compound to a drug tended to involve certain predictable changes in molecular properties, most notably marked increases in molecular weight (MW) and in lipophilicity. To assess how lead optimization practices have changed over the past 20 years, we examined oral drugs approved during 2020-2023 and their corresponding lead compounds with respect to their molecular properties. As well as comparing property averages, we analyzed the changes introduced in each individual drug discovery program to directly assess the trends that characterize the modern lead-to-drug process. We found that changes in MW from lead to drug are substantially smaller than in the older studies, with a median mass change corresponding to addition of just a single heavy atom, and cLogP is now slightly more likely to decrease than to become greater. Thus, the notion that lead optimization tends to involve making the compound ‘bigger and greasier’ no longer applies. Rather, approaches have been found to refine compound potency and selectivity, and to eliminate ADME liabilities, without adding substantial mass or overly relying on the hydrophobic effect as a driver of binding. One such tactic may be avoiding addition of aromatic groups during lead optimization, coupled with a tendency to favor heterocycles over aromatic carbocycles. Overall, our results imply that it may no longer be useful to think of ‘lead-like’ and ‘drug-like’ compounds as occupying distinct property space.